165 related articles for article (PubMed ID: 33032475)
1. Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive
Jiang X; Li X; Tu L; Cai J; Wei M; Wu Z; Sun L
J Int Med Res; 2020 Oct; 48(10):300060520955030. PubMed ID: 33032475
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
Cappuzzo F; Morabito A; Normanno N; Bidoli P; Del Conte A; Giannetta L; Montanino A; Mazzoni F; Buosi R; Burgio MA; Cerea G; Chiari R; Cortinovis D; Finocchiaro G; Foltran L; Migliorino MR; Tiseo M; Ferrari S; De Marinis F
Lung Cancer; 2016 Sep; 99():31-7. PubMed ID: 27565910
[TBL] [Abstract][Full Text] [Related]
4. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
Zhou Q; Zhang XC; Chen ZH; Yin XL; Yang JJ; Xu CR; Yan HH; Chen HJ; Su J; Zhong WZ; Yang XN; An SJ; Wang BC; Huang YS; Wang Z; Wu YL
J Clin Oncol; 2011 Aug; 29(24):3316-21. PubMed ID: 21788562
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.
Yoshida K; Yatabe Y; Park J; Ogawa S; Park JY; Shimizu J; Horio Y; Matsuo K; Mitsudomi T; Hida T
J Cancer Res Clin Oncol; 2010 Apr; 136(4):527-35. PubMed ID: 19777258
[TBL] [Abstract][Full Text] [Related]
6. [How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
Tang C; Li X; Guo W; Li J; Qin H; Wang W; Qu L; An J; Gao H; Liu X
Zhongguo Fei Ai Za Zhi; 2013 Jul; 16(7):345-52. PubMed ID: 23866664
[TBL] [Abstract][Full Text] [Related]
7. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Tang C; Gao H; Li X; Liu Y; Li J; Qin H; Wang W; Qu L; An J; Yang S; Liu X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):427-33. PubMed ID: 24401995
[TBL] [Abstract][Full Text] [Related]
8. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
[TBL] [Abstract][Full Text] [Related]
9. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.
Lim SW; Park S; Kim Y; Cho JH; Park SE; Lee H; Kim HK; Kim SM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2018 Oct; 124():293-297. PubMed ID: 30268476
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
11. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
Wu TH; Hsiue EH; Lee JH; Lin CC; Liao WY; Ho CC; Shih JY; Yu CJ; Yang JC
Clin Lung Cancer; 2018 May; 19(3):e361-e372. PubMed ID: 29477365
[TBL] [Abstract][Full Text] [Related]
12. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
Douillard JY; Ostoros G; Cobo M; Ciuleanu T; McCormack R; Webster A; Milenkova T
Br J Cancer; 2014 Jan; 110(1):55-62. PubMed ID: 24263064
[TBL] [Abstract][Full Text] [Related]
13. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
[TBL] [Abstract][Full Text] [Related]
14. The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Ko R; Kenmotsu H; Hisamatsu Y; Akamatsu H; Omori S; Nakashima K; Oyakawa T; Wakuda K; Shukuya T; Ono A; Imai H; Taira T; Naito T; Murakami H; Mori K; Endo M; Ohde Y; Takahashi K; Takahashi T
Int J Clin Oncol; 2015 Aug; 20(4):668-73. PubMed ID: 25343946
[TBL] [Abstract][Full Text] [Related]
15. Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib.
Nie X; Zhang P; Cheng G; Wu XN; Li L
Asia Pac J Clin Oncol; 2022 Feb; 18(1):150-155. PubMed ID: 33904654
[TBL] [Abstract][Full Text] [Related]
16. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
17. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
18. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
Imai H; Kuwako T; Kaira K; Masuda T; Miura Y; Seki K; Sakurai R; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Cancer Chemother Pharmacol; 2017 Mar; 79(3):497-505. PubMed ID: 28168310
[TBL] [Abstract][Full Text] [Related]
20. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Watanabe S; Tanaka J; Ota T; Kondo R; Tanaka H; Kagamu H; Ichikawa K; Koshio J; Baba J; Miyabayashi T; Narita I; Yoshizawa H
BMC Cancer; 2011 Jan; 11():1. PubMed ID: 21194487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
